BioCentury | Oct 24, 2020
Finance

Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris

New $461M venture fund for RA RA Capital raised $461 million for its Nexus Fund II, its second venture fund that like 2019’s $300 million Nexus I Fund will invest in private companies backed by the...
BioCentury | May 30, 2020
Politics, Policy & Law

Proposed changes to CFIUS rules would ensnare more Chinese-backed U.S. biotechs

A proposed regulation from the Department of Treasury could change what triggers CFIUS review of foreign investment in U.S.-based “critical technology” companies. The rule could increase mandatory filings for companies with investors from countries subject...
BioCentury | May 19, 2020
Regulation

Woodcock, Marks to recuse themselves from FDA reviews of COVID-19 products

FDA center directors Janet Woodcock and Peter Marks will not participate in reviews of COVID-19 products after taking on leadership roles in Operation Warp Speed, FDA Commissioner Stephen Hahn announced in an email to agency...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death. RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and...
BioCentury | Oct 18, 2019
Finance

Accelmed’s $100M fund targets early stage digital health plays

Israeli fund group Accelmed has launched a $100 million fund to invest in health-tech companies it views as attractive takeover targets. Accelmed Ventures II will focus on prerevenue med-tech and digital health companies in Israel...
BioCentury | Jul 15, 2019
Financial News

July 15 Financial Quick Takes: RA raises $300M for new fund; plus Alphamab and Castle

RA launches $300M VC fund RA Capital raised $300 million for its first close-ended venture fund, dubbed Nexus, which will invest in private companies backed by the firm's main fund, RA Capital Healthcare Fund L.P....
BioCentury | Apr 12, 2019
Emerging Company Profile

Bright Angel: New hope against fungal resistance

Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance...
BioCentury | Feb 14, 2019
Finance

HKEX: where East meets West

Unfazed by the shaky start of the Hong Kong stock exchange’s new biotech chapter, HKEX CEO Charles Li thinks its position at the nexus of East and West will underpin its long-term success. With more...
BioCentury | Dec 14, 2018
Tools & Techniques

Bigger sandbox for in silico tox

A consortium of companies and regulators could trigger a step change in how industry uses in silico toxicology to evaluate drug impurities and reduce the list of wet experiments required for regulatory submissions. So far,...
Items per page:
1 - 10 of 136
BioCentury | Oct 24, 2020
Finance

Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris

New $461M venture fund for RA RA Capital raised $461 million for its Nexus Fund II, its second venture fund that like 2019’s $300 million Nexus I Fund will invest in private companies backed by the...
BioCentury | May 30, 2020
Politics, Policy & Law

Proposed changes to CFIUS rules would ensnare more Chinese-backed U.S. biotechs

A proposed regulation from the Department of Treasury could change what triggers CFIUS review of foreign investment in U.S.-based “critical technology” companies. The rule could increase mandatory filings for companies with investors from countries subject...
BioCentury | May 19, 2020
Regulation

Woodcock, Marks to recuse themselves from FDA reviews of COVID-19 products

FDA center directors Janet Woodcock and Peter Marks will not participate in reviews of COVID-19 products after taking on leadership roles in Operation Warp Speed, FDA Commissioner Stephen Hahn announced in an email to agency...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death. RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and...
BioCentury | Oct 18, 2019
Finance

Accelmed’s $100M fund targets early stage digital health plays

Israeli fund group Accelmed has launched a $100 million fund to invest in health-tech companies it views as attractive takeover targets. Accelmed Ventures II will focus on prerevenue med-tech and digital health companies in Israel...
BioCentury | Jul 15, 2019
Financial News

July 15 Financial Quick Takes: RA raises $300M for new fund; plus Alphamab and Castle

RA launches $300M VC fund RA Capital raised $300 million for its first close-ended venture fund, dubbed Nexus, which will invest in private companies backed by the firm's main fund, RA Capital Healthcare Fund L.P....
BioCentury | Apr 12, 2019
Emerging Company Profile

Bright Angel: New hope against fungal resistance

Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance...
BioCentury | Feb 14, 2019
Finance

HKEX: where East meets West

Unfazed by the shaky start of the Hong Kong stock exchange’s new biotech chapter, HKEX CEO Charles Li thinks its position at the nexus of East and West will underpin its long-term success. With more...
BioCentury | Dec 14, 2018
Tools & Techniques

Bigger sandbox for in silico tox

A consortium of companies and regulators could trigger a step change in how industry uses in silico toxicology to evaluate drug impurities and reduce the list of wet experiments required for regulatory submissions. So far,...
Items per page:
1 - 10 of 136